Ascendis Pharma A/S (NASDAQ:ASND) Stock Keeps Overweight Rating at Cantor Fitzgerald

Ascendis Pharma A/S (NASDAQ:ASND)‘s stock had its “overweight” rating reiterated by equities researchers at Cantor Fitzgerald in a research report issued on Friday, Benzinga reports. They presently have a $300.00 target price on the biotechnology company’s stock. Cantor Fitzgerald’s price objective indicates a potential upside of 31.06% from the stock’s previous close.

Several other equities research analysts have also recently issued reports on ASND. Royal Bank Of Canada raised their target price on Ascendis Pharma A/S from $280.00 to $290.00 and gave the stock an “outperform” rating in a research note on Friday, August 14th. Oppenheimer lifted their price objective on Ascendis Pharma A/S from $304.00 to $312.00 and gave the company an “outperform” rating in a research note on Tuesday, September 1st. Wall Street Zen cut Ascendis Pharma A/S from a “buy” rating to a “hold” rating in a research note on Saturday. UBS Group reaffirmed a “buy” rating and issued a $344.00 price objective on shares of Ascendis Pharma A/S in a research note on Wednesday, September 16th. Finally, Stifel Nicolaus dropped their price objective on Ascendis Pharma A/S from $328.00 to $326.00 and set a “buy” rating for the company in a research note on Monday, August 31st. One analyst has rated the stock with a Strong Buy rating, nineteen have given a Buy rating and one has issued a Hold rating to the company. Based on data from MarketBeat.com, Ascendis Pharma A/S has a consensus rating of “Buy” and a consensus target price of $310.75.

Ascendis Pharma A/S Price Performance

NASDAQ ASND traded up $3.30 during trading hours on Friday, reaching $228.90. The company’s stock had a trading volume of 122,456 shares, compared to its average volume of 694,835. The firm has a market capitalization of $14.28 billion, a price-to-earnings ratio of 17.75 and a beta of 0.35. Ascendis Pharma A/S has a 1-year low of $186.05 and a 1-year high of $282.15. The company has a debt-to-equity ratio of 0.27, a current ratio of 2.99 and a quick ratio of 2.32. The company’s 50-day moving average is $251.52 and its two-hundred day moving average is $242.29.

Ascendis Pharma A/S (NASDAQ:ASND) last released its quarterly earnings results on Friday, August 14th. The biotechnology company reported $1.03 earnings per share for the quarter, missing analysts’ consensus estimates of $1.71 by ($0.68). The business had revenue of $387.22 million during the quarter, compared to analyst estimates of $376.75 million. Ascendis Pharma A/S had a return on equity of 32.54% and a net margin of 70.99%. On average, equities analysts predict that Ascendis Pharma A/S will post 3.69 EPS for the current year.

Insider Buying and Selling at Ascendis Pharma A/S

In other Ascendis Pharma A/S news, SVP Mads Bodenhoff sold 3,000 shares of the business’s stock in a transaction on Tuesday, September 8th. The shares were sold at an average price of $270.19, for a total transaction of $810,570.00. Following the completion of the sale, the senior vice president owned 3,000 shares in the company, valued at approximately $810,570. The trade was a 50.00% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, Director Jean-Jacques Bienaimé acquired 2,000 shares of the company’s stock in a transaction on Friday, August 14th. The stock was acquired at an average cost of $246.33 per share, for a total transaction of $492,660.00. Following the completion of the purchase, the director directly owned 2,900 shares of the company’s stock, valued at approximately $714,357. This represents a 222.22% increase in their position. The SEC filing for this purchase provides additional information. 40.00% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in the company. Perceptive Advisors LLC lifted its position in shares of Ascendis Pharma A/S by 41.6% during the first quarter. Perceptive Advisors LLC now owns 1,531,421 shares of the biotechnology company’s stock valued at $350,282,000 after purchasing an additional 450,000 shares in the last quarter. Fred Alger Management LLC grew its position in Ascendis Pharma A/S by 106.3% during the fourth quarter. Fred Alger Management LLC now owns 352,109 shares of the biotechnology company’s stock valued at $75,084,000 after buying an additional 181,408 shares during the period. Sei Investments Co. raised its position in Ascendis Pharma A/S by 24.8% in the first quarter. Sei Investments Co. now owns 351,146 shares of the biotechnology company’s stock worth $80,318,000 after acquiring an additional 69,673 shares during the period. Pictet Asset Management Holding SA raised its position in Ascendis Pharma A/S by 243.0% in the first quarter. Pictet Asset Management Holding SA now owns 251,833 shares of the biotechnology company’s stock worth $56,907,000 after acquiring an additional 178,415 shares during the period. Finally, Candriam S.C.A. raised its position in Ascendis Pharma A/S by 23.2% in the first quarter. Candriam S.C.A. now owns 230,278 shares of the biotechnology company’s stock worth $52,671,000 after acquiring an additional 43,338 shares during the period.

Ascendis Pharma A/S Company Profile

Ascendis Pharma A/S (NASDAQ:ASND) is a biopharmaceutical company focused on developing and commercializing therapies for rare diseases. The company uses its proprietary TransCon technology platform to design long-acting medicines intended to improve the effectiveness, convenience, and tolerability of established treatments.

Ascendis’ marketed products include Skytrofa (lonapegsomatropin-tcgd), a long-acting growth hormone approved for the treatment of growth hormone deficiency in children, and Yorvipath (palopegteriparatide), a hormone replacement therapy for adults with hypoparathyroidism.